President Trump announced the popular GLP-1 weight loss drugs would soon be more accessible to millions of Americans at a ...

On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from ...

Last August, Serena opened up to PEOPLE about her challenges with weight loss and how she feels "good and healthy" after ...

Memberships starting at $25 per month for insured patients give eligible members nationwide access to semaglutide and ...

A new GLP-1 weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which ...

Ashley Graham, 38, is a leading body positivity model and campaigner who has spoken out on the cultural impact of GLP-1 weight loss drugs like Mounjaro and Wegovy, branding them a "smack in the face" ...

Weekly injections of the GLP-1 semaglutide reduce alcohol consumption in patients with obesity seeking treatment for alcohol ...

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the ...

Starting a GLP-1 medication is a bit like making a deal with your body. You’re going to lose your appetite and probably some ...

After accounting for 14% of all prescription drug spending in 2025, the blockbuster GLP-1 drug class is on track to continue rapid growth and alter pharmaceutical spending trends.  For example, Eli ...

U.S. President Donald Trump announced on Friday that the federal government is taking steps to expand access to GLP-1 ...

An estimated one in eight adult Americans is currently taking a GLP-1 drug, according to KFF, a nonprofit focused on health ...